prof. Valerie Fonteyne

Journal Article
A1
open access

A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer

Elise De Bleser (UGent) , Ruben Willems (UGent) , Karel Decaestecker (UGent) , Lieven Annemans (UGent) , Aurélie De Bruycker (UGent) , Valerie Fonteyne (UGent) , Nicolaas Lumen (UGent) , Filip Ameye, Ignace Billiet, Steven Joniau, et al.

(2020) CANCERS. 12(1).

Add to list

Journal Article

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Petra Seibold, Adam Webb, Miguel E. Aguado-Barrera, David Azria, Celine Bourgier, Muriel Brengues, Erik Briers, Renée Bultijnck (UGent) , Patricia Calvo-Crespo, Ana Carballo, et al.

(2019) Radiotherapy and Oncology. 138. p.59-67

Add to list

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer - an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committees

A Horwich, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, S Gillessen, N James, S Maclennan, J Palou, et al.

(2019) ANNALS OF ONCOLOGY. 30(11). p.1697-1727

Add to list

Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer

Sarah Piron (UGent) , Kathia De Man (UGent) , Nick Van Laeken (UGent) , Yves D'Asseler (UGent) , Klaus Bacher (UGent) , Ken Kersemans (UGent) , Piet Ost (UGent) , Karel Decaestecker (UGent) , Pieter Deseyne (UGent) , Valerie Fonteyne (UGent) , et al.

(2019) JOURNAL OF NUCLEAR MEDICINE. 60(12). p.1736-1742

Add to list

Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results

Gillian Vandekerkhove, Nora Sundahl (UGent) , Karel Decaestecker (UGent) , Annabel Meireson (UGent) , Pieter De Visschere (UGent) , Valerie Fonteyne (UGent) , Daan De Maeseneer (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Jo Van Dorpe (UGent) , et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(7, suppl. 5).

Add to list

Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results

Piet Ost (UGent) , Nora Sundahl (UGent) , G Vandekerkhove, Karel Decaestecker (UGent) , Annabel Meireson (UGent) , Pieter De Visschere (UGent) , Valerie Fonteyne (UGent) , Daan De Maeseneer (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , et al.

(2019) EUROPEAN UROLOGY SUPPLEMENTS. 18(1). p.e2105-e2105

Add to list

Nodal oligorecurrent prostate cancer : anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates

Aurélie De Bruycker (UGent) , Elise De Bleser (UGent) , Karel Decaestecker (UGent) , Valerie Fonteyne (UGent) , Nicolaas Lumen (UGent) , Pieter De Visschere (UGent) , Kathia De Man (UGent) , Louke Delrue (UGent) , Bieke Lambert (UGent) and Piet Ost (UGent)

(2019) EUROPEAN UROLOGY. 75(5). p.826-833

Add to list

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

Elke Rammant (UGent) , Piet Ost (UGent) , Martijn Swimberghe (UGent) , Barbara Vanderstraeten (UGent) , Nicolaas Lumen (UGent) , Karel Decaestecker (UGent) , Renée Bultijnck (UGent) , Gert De Meerleer (UGent) , Camille Sarrazyn, Roos Colman (UGent) , et al.

(2019) STRAHLENTHERAPIE UND ONKOLOGIE. 195(5). p.393-401

Add to list

Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma

Nora Sundahl (UGent) , Gillian Vandekerkhove, Karel Decaestecker (UGent) , Annabel Meireson (UGent) , Pieter De Visschere (UGent) , Valerie Fonteyne (UGent) , Daan De Maeseneer (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Jo Van Dorpe (UGent) , et al.

(2019) EUROPEAN UROLOGY. 75(5). p.707-711

Add to list

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer : not ready for prime time

Bert Dhondt (UGent) , Elise De Bleser (UGent) , Tom Claeys, Sarah Buelens (UGent) , Nicolaas Lumen (UGent) , Jo Vandesompele (UGent) , Anneleen Beckers, Valerie Fonteyne (UGent) , Kim Van der Eecken (UGent) , Aurélie De Bruycker (UGent) , et al.

(2019) WORLD JOURNAL OF UROLOGY. 37(12). p.2557-2564

Academic Bibliography

prof. Valerie Fonteyne

A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer - an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committees

Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer

Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results

Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results

Nodal oligorecurrent prostate cancer : anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer : not ready for prime time

Contents

Support

Contact